Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Alveolar type II cells and pulmonary surfactant in COVID-19 era

A. Calkovska, M. Kolomaznik, V. Calkovsky

. 2021 ; 70 (S2) : S195-S208. [pub] 20211216

Language English Country Czech Republic

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc22000864

In this review, we discuss the role of pulmonary surfactant in the host defense against respiratory pathogens, including novel coronavirus SARS-CoV-2. In the lower respiratory system, the virus uses angiotensin-converting enzyme 2 (ACE2) receptor in conjunction with serine protease TMPRSS2, expressed by alveolar type II (ATII) cells as one of the SARS-CoV-2 target cells, to enter. ATII cells are the main source of surfactant. After their infection and the resulting damage, the consequences may be severe and may include injury to the alveolar-capillary barrier, lung edema, inflammation, ineffective gas exchange, impaired lung mechanics and reduced oxygenation, which resembles acute respiratory distress syndrome (ARDS) of other etiology. The aim of this review is to highlight the key role of ATII cells and reduced surfactant in the pathogenesis of the respiratory form of COVID-19 and to emphasize the rational basis for exogenous surfactant therapy in COVID-19 ARDS patients.

References provided by Crossref.org

Bibliography, etc.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc22000864
003      
CZ-PrNML
005      
20220217135129.0
007      
ta
008      
220106s2021 xr f 000 0|eng||
009      
AR
024    7_
$a 10.33549/physiolres.934763 $2 doi
035    __
$a (PubMed)34913352
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Čalkovská, Andrea $7 mzk2004236811 $u Department of Physiology, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic
245    10
$a Alveolar type II cells and pulmonary surfactant in COVID-19 era / $c A. Calkovska, M. Kolomaznik, V. Calkovsky
504    __
$a Literatura
520    9_
$a In this review, we discuss the role of pulmonary surfactant in the host defense against respiratory pathogens, including novel coronavirus SARS-CoV-2. In the lower respiratory system, the virus uses angiotensin-converting enzyme 2 (ACE2) receptor in conjunction with serine protease TMPRSS2, expressed by alveolar type II (ATII) cells as one of the SARS-CoV-2 target cells, to enter. ATII cells are the main source of surfactant. After their infection and the resulting damage, the consequences may be severe and may include injury to the alveolar-capillary barrier, lung edema, inflammation, ineffective gas exchange, impaired lung mechanics and reduced oxygenation, which resembles acute respiratory distress syndrome (ARDS) of other etiology. The aim of this review is to highlight the key role of ATII cells and reduced surfactant in the pathogenesis of the respiratory form of COVID-19 and to emphasize the rational basis for exogenous surfactant therapy in COVID-19 ARDS patients.
650    _2
$a pneumocyty $x účinky léků $x imunologie $x metabolismus $x virologie $7 D056809
650    _2
$a angiotensin-konvertující enzym 2 $x metabolismus $7 D000085962
650    _2
$a zvířata $7 D000818
650    _2
$a COVID-19 $x imunologie $x metabolismus $x virologie $7 D000086382
650    _2
$a interakce hostitele a patogenu $7 D054884
650    _2
$a lidé $7 D006801
650    _2
$a plíce $x účinky léků $x imunologie $x metabolismus $x virologie $7 D008168
650    _2
$a proteiny asociované s plicním surfaktantem $x metabolismus $7 D037661
650    _2
$a plicní surfaktanty $x terapeutické užití $7 D011663
650    _2
$a virové receptory $x metabolismus $7 D011991
650    _2
$a SARS-CoV-2 $x imunologie $x patogenita $7 D000086402
650    _2
$a serinové endopeptidasy $x metabolismus $7 D012697
650    _2
$a internalizace viru $7 D053586
650    _2
$a farmakoterapie COVID-19 $7 D000093485
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Kolomazník, Maroš $7 xx0233029 $u Martin Biomedical Centre, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic
700    1_
$a Čalkovský, Vladimír $7 xx0073397 $u Clinic of Otorhinolaryngology and Head and Neck Surgery, Jessenius Faculty of Medicine, Comenius University, University Hospital Martin, Martin, Slovak Republic
773    0_
$w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 70, Suppl. 2 (2021), s. S195-S208
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34913352 $y Pubmed
910    __
$a ABA008 $b A 4120 $c 266 $y p $z 0
990    __
$a 20220106 $b ABA008
991    __
$a 20220217135123 $b ABA008
999    __
$a ok $b bmc $g 1761111 $s 1152010
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 70 $c S2 $d S195-S208 $e 20211216 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
LZP    __
$b NLK118 $a Pubmed-20220106

Find record

Citation metrics

Archiving options